Here's how NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://pmc.ncbi.nlm.nih.gov/articles/PMC7227780/, but it redirected us to https://pmc.ncbi.nlm.nih.gov/articles/PMC7227780/. The analysis below is for the second page.

Title[redir]:
Metabolic reprogramming and cancer progression - PMC
Description:
Metabolic reprogramming is a hallmark of malignancy first recognized a century ago. In some cases, reprogrammed metabolic activities can be exploited to diagnose, monitor, and treat cancer. Stereotyped metabolic activities in cultured cancer ...

Matching Content Categories {๐Ÿ“š}

  • Health & Fitness
  • Science
  • Education

Content Management System {๐Ÿ“}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of ncbi.nlm.nih.gov audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 6,398,976 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {๐Ÿ’ธ}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Ncbi.nlm.nih.gov could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {๐Ÿ”}

doi, cancer, metabolic, google, scholar, pubmed, cells, pmc, article, free, tumors, tumor, cell, mutations, metabolism, nature, metastasis, lung, growth, metastatic, human, therapeutic, models, progression, pathways, kras, oncogenic, oxidative, expression, reprogramming, inhibitors, lesions, tissue, oxphos, primary, science, glutamine, phenotypes, cancers, clinical, including, heterogeneity, liabilities, fig, mice, enhanced, breast, properties, promote, studies,

Topics {โœ’๏ธ}

methyl-4-deoxy-4-[18f]-fluoro-ฮฑ-d-glucopyranoside ฮฑ-ketoglutarate-dependent enzyme prolyl-4-hydroxylase glutamine analog 6-diazo-5-oxo-l-norleucine inhibit ฮฑ-ketoglutarate-dependent enzymes homologous-recombination dna repair magnetic resonance spectroscopy targeting metastasis-initiating cells pdac-induced macrophage polarization stimulates collagen cross-linking pmc beta search inhibit vhl-dependent degradation excessive collagen cross-linking serine-threonine kinase lkb1 hypoxia-inducible factor-ฮฑ triple-negative breast cancer fatty acid oxidation regenerate ros-detoxifying metabolites tumor-induced gene expression mct1-dependent lactate transport additional subtype-selective metabolic renal cell carcinoma sporadic tp53-mutant cancers lkb1-mutant lung cancer cultured cancer cellsโ€“notably kras-mutant lung adenocarcinoma small-cell lung cancers growth-promoting metabolic network primary invasive cancers acquire cell-autonomous properties locally invasive cancers d-2hg inhibits enzymes patient-derived melanoma xenografts lymph node metastases early-stage lung adenocarcinoma patient-specific tumor metabolism small-cell lung cancer combinatorial cell-intrinsic effects cell-autonomous adaptive resistance low-glucose conditions selects impair hematopoietic differentiation premalignant lesions relative oncogene-dependent activation invasive cancer cells targetable metabolic vulnerability kras-stk11 metabolic phenotype cell-autonomous metabolic effects locally invasive tumors oncogene-driven liabilities acute myelogenous leukemia low genomic burden

Questions {โ“}

  • How then should we prioritize potential metabolic liabilities for further study and the development of new therapies?
  • Is the therapeutic window for OXPHOS inhibitors wide enough, given that this pathway is so important in many other tissues?

External Links {๐Ÿ”—}(260)

Analytics and Tracking {๐Ÿ“Š}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Foundation
  • jQuery
  • jQuery module (jquery-3.6.0)
  • Zoom.js

Emails and Hosting {โœ‰๏ธ}

Mail Servers:

  • nihcesxway.hub.nih.gov
  • nihcesxway2.hub.nih.gov
  • nihcesxway3.hub.nih.gov
  • nihcesxway4.hub.nih.gov
  • nihcesxway5.hub.nih.gov

Name Servers:

  • dns1-ncbi.ncbi.nlm.nih.gov
  • dns2-ncbi.ncbi.nlm.nih.gov
  • lhcns1.nlm.nih.gov
  • lhcns2.nlm.nih.gov

CDN Services {๐Ÿ“ฆ}

  • Ncbi

4.03s.